Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2010

01-03-2010 | Letter to the Editor

Non-cirrhotic extrahepatic portal vein thrombosis: a 6-year long case history

Authors: Giorgio Ricci, Flavia Pigò, Angelo Rossi, Gianluca Bersani, Vittorio Alvisi

Published in: International Journal of Hematology | Issue 2/2010

Login to get access

Excerpt

In the absence of liver cirrhosis or cancer, splanchnic vein thrombosis is rare. Additional risk factors are neoplasia, abdominal inflammatory disease, and inherited and acquired thrombophilia as reported in chronic myeloproliferative disorders (CMPD), i.e. polycythemia vera and essential thrombocythemia [1, 2]. The Janus kinase-2 somatic mutation (JAK2V617F) represents a risk factor for myeloproliferative diseases and is helpful in laboratory tests for the evaluation of unexplained abdominal vein thrombosis [3‐5]. …
Literature
1.
Webster GJM, Burroughs AK, Riordan SM. A review article: portal vein thrombosis, new insights into etiology and management. Aliment Pharmacol Ther. 2005;21:1–9.CrossRefPubMed
2.
3.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer genome project: acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.PubMed
4.
Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–34.CrossRefPubMed
5.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed
6.
P’ng S, Carnley B, Baker R, Kontorins N, Cheng W. Undiagnosed myeloprolipherative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation. Clin Gastroenterol Hepatol. 2008;6:472–5.CrossRefPubMed
Metadata
Title
Non-cirrhotic extrahepatic portal vein thrombosis: a 6-year long case history
Authors
Giorgio Ricci
Flavia Pigò
Angelo Rossi
Gianluca Bersani
Vittorio Alvisi
Publication date
01-03-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0507-y

Other articles of this Issue 2/2010

International Journal of Hematology 2/2010 Go to the issue

Letter to the Editor

Rituximab therapy for refractory immune thrombocytopenic purpura in elder patients

Original Article

Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children: a retrospective multi-center study

Original Article

Interaction of SDF-1α and CXCR4 plays an important role in pulmonary cellular infiltration in differentiation syndrome

Original Article

Adult bone marrow cells can differentiate into hemopoietic cells and endothelial cells but not into other lineage cells in normal growth and normal life

Case Report

Autoimmune haemolytic anaemia associated with mantle cell lymphoma

Letter to the Editor

Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits